Provectus Biopharmaceuticals Signs Agreement with China's Tririver Capital
Business Wire - Mon Apr 14, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
Induction of Systemic Immunity Following Treatment of Tumors with PV-10 Reported by Moffitt Cancer Center Researchers at American Association for Cancer Research Annual Meeting
Business Wire - Mon Apr 07, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
Provectus Biopharmaceuticals' PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at the American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire - Wed Apr 02, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire - Tue Apr 01, 5:30AM CDT
--McCormick Place in Chicago, IL, May 30-June 3, 2014
Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference
Business Wire - Tue Apr 01, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
Provectus Biopharmaceuticals expects US FDA's Breakthrough Therapy Designation for PV-10 for melanoma within 60 days of receipt of application
M2 - Tue Mar 25, 6:14AM CDT
Biopharmaceutical company Provectus Biopharmaceuticals (Other OTC
Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma
Business Wire - Mon Mar 24, 5:05AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
Provectus names Dr Joseph M. Chalil to strategic advisory board
M2 - Thu Mar 20, 8:20AM CDT
Oncology company Provectus Biopharmaceuticals (Other OTC
Provectus names Dr Joseph M. Chalil to Strategic Advisory Board
M2 - Wed Mar 19, 8:34AM CDT
Provectus Biopharmaceuticals, Inc. (OTC: PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced the appointment of Dr Joseph M. Chalil to its strategic advisory board.
Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD
PR Newswire - Thu Mar 13, 11:04AM CDT
Provectus Pharmaceuticals, Inc. (OTC: PVCT) The melanoma version of the drug is the closest to market release. Phase 2 data was finalized in October 2012 and the drug is being prepped for Breakthrough Therapy Designation (BTD) Drug Submission with the FDA and is in the final steps for approval. Once submitted PVCT should receive a decision within 60 days of receipt of that request.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Sanofi's CEO Admits Lackluster Drug Development Decade but Defends Its Pipeline: Sanofi (OTCQB: SNYNF), Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Feb 10, 10:12AM CST
The fierce competition coming from generic drug companies, the escalating costs of developing new drugs and the arduous process of getting them approved weighs heavily on Sanofi (OTCQB: SNYNF) and its competitors.
TrendingWallStreet.com Begins Trending PVCT, ORMP, KO, and MCIG
ACCESSWIRE - Mon Feb 03, 11:27PM CST
Whether it's a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown
at The Street - Fri Jan 31, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Tranzbyte's Medical-Marijuana Dispensary Deal Falls Apart: Tranzbyte Corp. (OTCPINK: ERBB), Neutra Corp. (OTCQB: NTRR), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Thu Jan 30, 8:47AM CST
Tranzbyte Corp. (OTCPINK: ERBB) was forced to take back the good news that it had struck a deal with a medical-marijuana dispensary to use the dispensary units it sells.
CORRECTION: Provectus's PV-10 path to initial approval in US now clear per FDA meeting minutes
M2 - Tue Jan 28, 9:11AM CST
Correction to headline: Provectus Biopharmaceuticals Inc (OTC
Federal Court Ruling Could Be Set Back for Royal Dutch Shell Stock: Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Sanofi (OTCQB: SNYNF), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Jan 27, 2:01PM CST
Whether a recent federal court ruling will scrap Royal Dutch Shell Plc (OTCQB: RYDAF) Alaska drilling plans remains to be seen, but the uncertainty it creates could affect the oil company's share price.
Provectus announces clearance of initial approval for PV-10 in US
M2 - Mon Jan 27, 6:23AM CST
Provectus Biopharmaceuticals Inc (OTC